Patents by Inventor Isis Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130331435Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.Type: ApplicationFiled: May 30, 2013Publication date: December 12, 2013Applicant: Isis Pharmaceuticals, Inc.Inventor: Isis Pharmaceuticals, Inc.
-
Publication number: 20130296400Abstract: The present invention relates to antisense antidote compounds and uses thereof. Such antidote compounds reduce the magnitude and/or duration of the antisense activity of an antisense compound.Type: ApplicationFiled: March 4, 2013Publication date: November 7, 2013Applicant: ISIS PHARMACEUTICALS, INC.Inventor: Isis Pharmaceuticals, Inc.
-
Publication number: 20130274309Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: ApplicationFiled: January 7, 2013Publication date: October 17, 2013Applicant: Isis Pharmaceuticals, Inc.Inventor: Isis Pharmaceuticals, Inc.
-
Publication number: 20130211064Abstract: The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, tetrahydropyran nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.Type: ApplicationFiled: April 17, 2013Publication date: August 15, 2013Applicant: Isis Pharmaceuticals, Inc.Inventor: Isis Pharmaceuticals, Inc.
-
Publication number: 20130197062Abstract: The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.Type: ApplicationFiled: March 21, 2013Publication date: August 1, 2013Applicant: Isis Pharmaceuticals, Inc.Inventor: Isis Pharmaceuticals, Inc.
-
Publication number: 20130190384Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: ApplicationFiled: December 4, 2012Publication date: July 25, 2013Applicant: Isis Pharmaceuticals, Inc.Inventor: Isis Pharmaceuticals, Inc.
-
Publication number: 20130189782Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.Type: ApplicationFiled: December 7, 2012Publication date: July 25, 2013Applicants: CHDI Foundation Inc., Isis Pharmaceuticals, Inc.Inventors: Isis Pharmaceuticals, Inc., CHDI Foundation Inc.
-
Publication number: 20130178513Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.Type: ApplicationFiled: February 28, 2013Publication date: July 11, 2013Applicant: ISIS PHARMACEUTICALS, INC.Inventor: ISIS PHARMACEUTICALS, INC.
-
Publication number: 20130164844Abstract: The present invention provides method of optimizing the efficacy and potency of antisense drugs. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipeints for improved cellular uptake.Type: ApplicationFiled: October 23, 2012Publication date: June 27, 2013Applicant: Isis Pharmaceuticals, Inc.Inventor: Isis Pharmaceuticals, Inc.
-
Publication number: 20130165496Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: ApplicationFiled: October 26, 2012Publication date: June 27, 2013Applicant: Isis Pharmaceuticals, Inc.Inventor: Isis Pharmaceuticals, Inc.
-
Publication number: 20130150425Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GCCR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.Type: ApplicationFiled: October 25, 2012Publication date: June 13, 2013Applicant: Isis Pharmaceuticals, Inc.Inventor: Isis Pharmaceuticals, Inc.
-
Publication number: 20130143943Abstract: Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for diagnosis and treatment of diseases and conditions associated with expression of glucocorticoid receptor are provided.Type: ApplicationFiled: October 12, 2012Publication date: June 6, 2013Applicant: Isis Pharmaceuticals, Inc.Inventor: Isis Pharmaceuticals, Inc.
-
Publication number: 20130144044Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.Type: ApplicationFiled: January 15, 2013Publication date: June 6, 2013Applicant: ISIS PHARMACEUTICALS, INC.Inventor: ISIS PHARMACEUTICALS, INC.
-
Publication number: 20130116301Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GCGR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.Type: ApplicationFiled: September 20, 2012Publication date: May 9, 2013Applicant: Isis Pharmaceuticals, Inc.Inventor: Isis Pharmaceuticals, Inc.
-
Publication number: 20130109091Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.Type: ApplicationFiled: December 19, 2012Publication date: May 2, 2013Applicants: Cold Spring Harbor Laboratory, Isis Pharmaceuticals, Inc.Inventors: Isis Pharmaceuticals, Inc., Cold Spring Harbor Laboratory
-
Publication number: 20130079387Abstract: Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating or preventing conditions, including hyperproliferative conditions, associated with raf expression.Type: ApplicationFiled: November 15, 2012Publication date: March 28, 2013Applicant: ISIS PHARMACEUTICALS, INC.Inventor: ISIS PHARMACEUTICALS, INC.
-
Publication number: 20130053431Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.Type: ApplicationFiled: October 18, 2012Publication date: February 28, 2013Applicants: Isis Pharmaceuticals, Inc., Antisense Therapeutics LimitedInventors: Antisense Therapeutics Limited, Isis Pharmaceuticals, Inc.